Background. Young children with intestinal failure are at risk for complications from rotavirus gastroenteritis. To date, the safety and immunogenicity of rotavirus vaccines in these children are not known. We hypothesized that rotavirus vaccination would be safe and confer immunity to infants with intestinal failure and a history of abdominal surgery. Methods. The study population consisted of infants with early intestinal failure who required abdominal surgery and parenteral nutrition for necrotizing enterocolitis, gastroschisis, jejunoileal atresia, or meconium peritonitis. Subjects received a rotavirus vaccine series at the appropriate age. Safety assessments were performed for the first 5 days after each vaccine dose. Viral stool shedding and serum rotavirus antigen were measured at multiple time points after each dose of the vaccine. A 3-fold increase in rotavirus immunoglobulin A titer at study completion defined seroconversion. Results. Fifteen infants were enrolled and 14 infants completed the study protocol. Mild diarrhea, emesis, and fever were noted after vaccination in 33%, 40%, and 7% of subjects, respectively. No subject experienced postvaccine intussusception, viremia, dehydration, or required alterations in nutritional care. Viral stool shedding was noted in 47%, but only 1 child shed virus beyond 2 weeks postvaccination. All subjects who were not considered immune at baseline developed seroconversion to rotavirus after vaccination. Conclusions. In infants with intestinal failure, rotavirus vaccination appears to be safe and immunogenic. We found no evidence for altered viral shedding in this population. Given the profound consequences associated with rotavirus infection and potential benefits of rotavirus vaccine in this cohort, multicenter studies focusing on vaccine efficacy are warranted.
To date, there are no data available to assess the safety of rotavirus vaccines in children with intestinal failure. Indeed, the pathophysiology inherent to intestinal failure may complicate the safety and immunogenicity of an oral vaccine. For example, children with intestinal failure are prone to have a decreased small bowel absorptive capacity, profound alterations in gut motility, and frequent episodes of bacterial overgrowth [14] . Their gut-associated lymphatic tissue may be disordered from resection or anatomic variation. It is not known how an oral rotavirus vaccine would be absorbed and processed in this population. The Advisory Committee on Immunization Practices (ACIP) from the Centers for Disease Control and Prevention (CDC) currently recommends vaccination with rotavirus vaccines in infants with preexisting chronic gastrointestinal conditions while acknowledging the lack of data to guide this decision [15] .
The primary objective of this study was to assess the safety and immunogenicity of an approved oral rotavirus vaccine in infants who have undergone surgical treatment for early intestinal failure. In addition, we sought to measure viral stool shedding patterns and the presence of systemic rotavirus absorption as measured by serum antigen in this high-risk population.
METHODS

Study Population
This was a prospective, intervention study designed to assess the safety of the 2-dose monovalent rotavirus vaccine (RV1) in infants with early intestinal failure. Monovalent rotavirus vaccine was used in this pilot study because specimen collection schedule and safety data acquisition was believed to be more convenient for families when a 2-dose vaccine was used. Infants were included if they were between 6 and 14 weeks of age, had undergone surgical treatment for gastroschisis, necrotizing enterocolitis, jejuno-ileal atresia, total colonic Hirschsprungs disease, midgut volvulus, or complicated meconium peritonitis, and required parenteral nutrition postoperatively. Subjects were excluded for any of the following: immunocompromise secondary to human immunodeficiency virus infection or other immunodeficiency state; active administration of corticosteroid or other immunosuppressive agent; severe malnutrition as defined by a serum albumin less than 2.0 mg/dL; or active infection defined by fever greater than 38°C within 24 hours, positive blood culture within 7 days, or positive urine culture within 3 days of planned vaccine administration.
Study Protocol
The study protocol was approved by the Seattle Children's Institutional Review Board (IRB No. 12940). Enrollment commenced in December 2009, and the last study visit occurred in January 2012. After informed consent was provided, baseline stool and serum samples were obtained immediately before or within 1 day of administration of the first vaccine dose. The study protocol specified the monovalent rotavirus vaccine, a human, live-attenuated vaccine containing a rotavirus strain of G1P1A [8] specificity. The liquid vaccine (1 mL) was administered orally in children who were able to tolerate oral intake and by nasogastric feeding tube in children who were not fed orally. The second dose of the vaccine was administered at a minimum of 8 weeks after the first dose. A detailed safety survey was completed by a study team member for each of the first 5 days after each vaccine dose (see Appendix). For inpatients, the safety survey was performed by bedside physical examination and review of the patient's clinical flowsheet. For outpatients, the safety survey was performed by telephone interview with the subject's primary caregiver. Parents of outpatient subjects were asked to measure the patient's temperature daily (and when fever was suspected) for 5 days after each vaccine dose.
Beginning in March 2010, during active enrollment for this study, the Food and Drug Administration (FDA) temporarily advised against the use of the RV1 vaccine due to the discovery of viral fragments in the vaccine [16] . It was later determined that there was no health risk, and as of May 2010, both vaccines were again recommended for routine administration. To comply with the FDA recommendation, the study protocol was temporarily amended to include the use of the 3-dose pentavalent RV5 rotavirus vaccine for a period of 2 months in 2010. This protocol modification affected 2 subjects who had received the first dose of the RV1 vaccine and were awaiting the second dose at the time of the FDA's suspension of the vaccine. These subjects completed the study protocol by receiving 2 additional doses of the pentavalent vaccine at 6-week intervals. The 5-day safety survey and specimen collection were performed after each additional vaccine dose.
Stool samples were obtained at weeks 1, 2, and 4 after each dose of the vaccine to measure viral antigen. Stool samples were obtained from the subjects' diaper or directly from an ostomy bag in patients who were not in intestinal continuity. Because rotavirus antigenemia has been documented in young children during active rotavirus infection, serum samples were obtained at weeks 1 and 2 after each vaccine dose to assess the presence of viral antigen in the bloodstream [17] . Serum immunoglobulin A (IgA) antibody to rotavirus was measured immediately before the first and second doses of the vaccine and at the end of the study protocol (4 weeks after the final dose of the vaccine). All samples were stored at -20 o C. Identification of rotavirus antigen in the stool or sera was performed using an enzymelinked immunosorbent assay described previously [18] . Immunoassay techniques were used to measure the titer of serum IgA antibody to rotavirus [19] .
At 6 months after the first vaccine dose, a follow-up phone call was made to parents of subjects to inquire about episodes of intussusception and interval hospital admissions for gastroenteritis and rotavirus infection. Parents were also asked whether the rotavirus vaccine, in their opinion, had caused any harmful effects to their child.
Outcome Measures and Statistical Analysis
Stool shedding was defined as the presence of detectable rotavirus antigen in subjects' stool at any time other than the prevaccine stool specimen. Serum antigenemia was measured by detection of rotavirus antigen in the serum. Similar to previous studies of rotavirus vaccine safety, immunogenicity was defined as a 3-fold increase in serum anti-rotavirus IgA antibody at least 4 weeks after the last vaccine dose compared with baseline measurement [15, 20] . Safety variables measured before and after vaccine administration included stool volume and frequency, fever, frequency of vomiting, generalized allergic reaction, and intussusception. We defined diarrhea as a greater than 2-fold increase in stool volume (when measured) or a 3-fold increase in stool frequency. Diarrhea or vomiting was defined as severe if it resulted in any change in the patient's enteral or intravenous feeding regimen. Fever was defined as a core body temperature >38.5°C, and generalized allergic reaction was defined as any significant change in the patient's daily physical exam or appearance that could not be attributed to a clinical source. In-hospital length of stay was determined from subjects' index admission to our hospital.
The analysis of this study was descriptive in nature. Demographic and laboratory characteristics were summarized for participants using number (percent) for categorical variables and median (range) for continuous variables. Safety data were summarized by the number (percent) of patients experiencing the event. Descriptive statistics were generated using the statistical software R version 2.12.2.
RESULTS
Twenty-five families of infants who met inclusion criteria were approached, and 15 infants including 8 females were enrolled in the study (Figure 1 ). Detailed data on enrolled subjects are presented in Table 1 . Diagnoses included gastroschisis (n = 7), necrotizing enterocolitis (n = 5), jejuno-ileal atresia (n = 1), gastroschisis with intestinal atresia (n = 1), and complicated meconium peritonitis (n = 1). Measureable bowel lengths were available in 4 subjects, and the median remnant bowel length after resection was 40 cm (range, 36-90). All subjects required parenteral nutrition for a median of 51 days (range, 25-554) and were hospitalized for 71 days (range, 41-189) initially after birth. Two subjects remain dependent on parenteral nutrition at 2 and 3 years of age, respectively. Subjects' direct bilirubin and albumin levels were 1.1 (range, 0.0-8.8) mg/dL and 2.9 (range, 2.4-3.7) mg/dL, respectively, at the first vaccine dose.
Fourteen subjects completed the study protocol. One subject elected to withdraw from the study immediately before the second vaccine dose due to difficulties with transportation to our institution; for this subject, safety data were collected for the first vaccine dose although no serum for postvaccine IgA measurement was available. From the entire study cohort, we collected 107 of 127 (86%) of projected stool specimens, 57 of 64 (89%) of serum samples for viremia testing, and 45 of 47 (96%) of serum samples for IgA measurement.
Postvaccine safety data demonstrated diarrhea in 5 (33%) subjects, vomiting in 6 (40%) subjects, and worsening diaper rash in 2 (13%) subjects. No subject experienced severe diarrhea or emesis, dehydration, or required Figure 1 . Twenty-five families were approached and 15 patients were enrolled. One patient dropped out of the study after completing the safety evaluation for the first vaccine dose due to transportation issues. Of the10 families who declined participation, the most common reasons included the inability to attend multiple study visits and a general concern for vaccine-related gastrointestinal side-effects in children who had recently undergone abdominal surgery. One subject withdrew from the study just before the second dose of RV1.
c One subject was vaccinated on postoperative day 1 after a liver biopsy and cholangiogram that did not involve bowel resection.
alterations in clinical or nutritional management in the initial 5 days after each vaccine dose. Only 1 subject experienced more than 4 total episodes of emesis throughout the entire 10-day safety collection period. One subject (7%) developed a fever of 38.7°C after the second dose of the vaccine. Irritability in the first 5 days after vaccination was noted in 9 (60%) patients. There were no episodes of intussusception during the study period, and no unanticipated adverse events were observed. A summary of reactogenicity in the study population is presented in Table 2 . Laboratory testing revealed no instances of rotavirus antigen in stool samples before the first vaccine dose. Postvaccine rotavirus shedding in the stool was noted in 7 (47%) subjects. Of these infants, 5 shed virus within the first week of vaccine dosing. Only 1 subject had documented viral shedding beyond 2 weeks postvaccine. Shedding was observed in 4 subjects after the first vaccine dose, 4 subjects after the second dose, and 1 subject after the third dose of the pentavalent rotavirus vaccine (Figure 2) . No patient had detectable serum viral antigen after vaccine administration.
Of the 15 subjects, 14 infants had postvaccination antibody levels measured. Seroconversion for serum antirotavirus IgA antibody was detected in 12 (86%) subjects at completion of the study protocol, and the remaining 2 (14%) subjects had an elevation in serum IgA antibody to rotavirus before the vaccine. Pre-and postvaccine serum anti-rotavirus IgA antibody levels for each subject are presented in Figure 3 . Seroconversion to rotavirus was noted in both subjects who received monovalent rotavirus vaccine followed by 2 doses of pentavalent rotavirus vaccine. Of the 2 subjects with an elevated baseline serum IgA antibody to rotavirus, 1 infant received a packed red blood cell transfusion 1 week before initial antibody measurement.
The 6-month postvaccination telephone interview was completed in 12 subjects, and 3 subjects were lost to longterm follow-up. One subject had been admitted for treatment of presumed gastroenteritis, and the stool culture was negative for rotavirus antigen by family report. There One subject withdrew from the study immediately before administration of the second vaccine dose. Therefore, safety data for this subject are only available for a single vaccine dose. Figure 2 . The number of subjects with laboratory-confirmed rotavirus stool shedding at each study time point did not differ from previously published data. Only 1 subject experienced prolonged viral stool shedding in this cohort. The total number of stool samples analyzed at each time point is indicated above the bar.
were no episodes of intussusception in the interval between completion of the study protocol and the follow-up interview. All contacted families affirmed that the rotavirus vaccine did not cause any harmful effects in their child.
DISCUSSION
In recent years, rotavirus vaccination has been associated with a significant reduction in hospitalizations, outpatient clinic visits, and emergency room evaluations for rotavirus gastroenteritis in the United States [1] [2] [3] . In numerous trials, the currently approved forms of the vaccine have been shown to be safe in healthy infants [15, [20] [21] [22] [23] .
There is now widespread agreement that rotavirus vaccine should be administered universally to young infants, and the ACIP has recommended routine use in infants with chronic gastrointestinal disorders. There are no published data describing the safety and efficacy of the rotavirus vaccine in infants with chronic gastrointestinal disease, such as intestinal failure secondary to short bowel syndrome. Children with intestinal failure are usually dependent on parenteral nutrition for prolonged periods secondary to altered gastrointestinal absorption, motility, and anatomy. They may suffer from gut-specific complications such as bowel obstruction, intraluminal bacterial overgrowth, and bacterial translocation. Because the rotavirus vaccine is processed at least initially by the enterocyte, there is reason to question the safety and effectiveness of an oral vaccine in this population. At the same time, there is evidence that children with intestinal failure have more severe sequelae from rotavirus gastroenteritis, thereby making the study of the rotavirus vaccine in this population clinically relevant [7] [8] [9] [10] .
The present pilot study evaluated the safety of an approved rotavirus vaccine in infants with early intestinal failure. These children required abdominal surgery in the initial neonatal period and had relatively long courses of parenteral nutrition after birth. Although many of these subjects would ultimately wean from parenteral nutrition during their initial hospital admission, they had significant gastrointestinal morbidity and would not have been previously included in clinical trials for vaccine safety. Thus, our study cohort represented a uniquely complicated patient population in whom routine and timely immunization against rotavirus remains controversial.
The data demonstrate that our subjects tolerated rotavirus vaccine without serious adverse effects. Whereas many subjects were irritable after the vaccine, the incidence of fever in this cohort was much less than expected from previously published data. Although the study relied on parental report of symptoms for outpatient subjects, we did find an increase in stool output and vomiting in a minority of patients. Phase III trials of the currently approved vaccines have reported an incidence of postvaccine diarrhea and emesis of up to 24% and 18%, respectively [15] . Nonetheless, the subjects in the current study did not require clinical changes in their medical or nutritional management (such as increases in intravenous fluids or restrictions on enteral feeding regimens) and did not manifest severe diarrhea or emesis after vaccine administration. Therefore, whereas mild gastrointestinal symptoms may be expected in this population after rotavirus vaccine administration, our data did not demonstrate clinically relevant consequences of these symptoms. This observation is corroborated by our 6-month follow-up data that demonstrate a unanimous opinion among families that the vaccine did not impart any harmful effects to their child. It should also be noted that stool output in this population is inherently difficult to measure, and the definitions used for this study may be liberal enough to overestimate an actual pathologic increase in stool production after vaccination.
The incidence of postvaccine viral stool shedding in our study population was similar to published data from healthy infants. Multiple Phase II and III studies have demonstrated viral stool shedding after RV1 in 50%-80% of healthy infants at 1 week and 19%-64% of healthy infants at 15 days [15] . At 60 days postvaccine, stool shedding was still seen in 0%-2.6% of healthy infants, although RV5 is associated with less viral stool shedding at each measured time point in Phase III trials. It is thought that viral stool shedding peaks at the end of the first week after the initial vaccine dose and stool shedding after the second dose is significantly less at each time interval. We found prolonged stool shedding in only 1 subject, an infant with gastroschisis who continued to shed virus at 8 weeks after the first vaccine dose and 4 weeks after the second dose. Interestingly, we found similar patterns of stool shedding after both the first and subsequent vaccine doses ( Figure 2 ). Based on these preliminary data, transmission of rotavirus due to shedding after vaccination may be no more likely to occur from infants with intestinal failure than from healthy infants, although additional studies are warranted.
The data on seroconversion to rotavirus were more straightforward. All subjects who did not have an elevation in rotavirus-specific antibody at baseline developed seroconversion to rotavirus at the end of the 12-week study protocol. This observation occurred despite clear impairments in the bowel function of our subjects shortly after birth. For example, one subject with a history of complicated meconium peritonitis requiring bowel resection developed a small bowel fistula at 25 cm from the ligament of Treitz early in her postoperative course; it was thought that her proximal small bowel drained entirely through this fistula, and she did not stool per rectum before her vaccination. Despite her gastrointestinal morbidity and lack of intestinal continuity, this subject developed an immunogenic response to the vaccine as measured by IgA titers after both the first and second doses of the vaccine. Because the study protocol used the RV1 vaccine primarily, these data may be specific to the RV1-RV1 vaccine regimen.
These data suggest that infants with early intestinal failure are able to effectively process a live attenuated oral vaccine similar to healthy infants despite alterations in intestinal motility, absorption, and length. This fact is relevant to the care of young infants who undergo abdominal surgery. Many of these patients will wean from parenteral nutrition and have a normal life expectancy. There is every reason to think that routine vaccination strategies will benefit these children just as much, if not more so, than healthy infants. These data support the use of the standard rotavirus vaccine administration schedule as recommended by the CDC in infants who have undergone intestinal surgery early in life. In addition, because infants with more advanced forms of intestinal failure have shown an increased propensity to get severe rotavirus infection, appropriately timed vaccination against rotavirus may benefit this cohort well into early childhood.
This study was limited by the small number of enrolled subjects and the fact that most of the subjects weaned completely from parenteral nutrition before discharge from their first inpatient admission. It follows that many of these patients did not suffer from chronic intestinal failure as seen in children with severe short bowel syndrome. Furthermore, detailed measurement of stool output before vaccine use was not rigorously evaluated, and the methods used to monitor stool output in these infants were relatively inexact. Finally, infants who received blood transfusion were not excluded from participation in this study. Therefore, it is possible that baseline elevations in anti-rotavirus IgA antibody could be related to blood product administration rather than exposure to viral antigen in the hospital setting.
A future intervention study evaluating the safety of a rotavirus vaccine in infants with the most advanced forms of short bowel syndrome would be clinically relevant, and the data would help to better define how patients with limited bowel length process an oral vaccine. However, such a clinical trial in this medically complex patient population would likely require a multi-institutional framework given the rare incidence of diagnoses that lead to chronic intestinal failure.
